HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Future Of OTCs: Self-Selection Meets Diagnostics, Genetic Personalization

This article was originally published in The Tan Sheet

Executive Summary

The next generation of consumer health products, including Rx-to-OTC switch opportunities, may work in concert with cutting-edge diagnostic tools and elements of personalized medicine, says Andrew Fish.

You may also be interested in...

CHPA Product Quality & Operations Workshop In Brief

Facilitating switch is CHPA’s top priority

Prepaid Cards Could Help OTC Switches Gain Against Rx Competitors

Medagate Corp.’s payment technology that simplifies insurance reimbursement for OTCs could help level the playing field with competing prescription products.

FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking

A draft guidance on designing self-selection studies in support of Rx-to-OTC switches reflects FDA’s interest in drilling down for greater insight into consumers’ thought processes.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts